USFDA cautions Aurobindo Pharma's oral solids formulation facility of regulatory action

According to USFDA's definitions, OAI means "objectionable conditions
were found and regulatory administrative sanctions by FDA are
indicated" during inspections. The company said that it believes that
this OAI classification will not have any material impact on the
existing revenues or the supplies to its US business at this juncture.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-cautions-aurobindo-pharmas-oral-solids-formulation-facility-of-regulatory-action/articleshow/73761421.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment